Zhen Wang

Zhen Wang

Auto-generated profile, based on publicly available information

Zhen Wang

Senior Department of Orthopedics, The Fourth Medical Centre, Chinese PLA General Hospital, Beijing, China

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 August 2019 in Molecular Carcinogenesis
Verified
Journal Article
Closed access
PDF file
QZQiangqiang Zhu
Qiangqiang Zhu
YWYiqi Wu
Yiqi Wu
MYMengli Yang
Mengli Yang
ZWZhen Wang
Zhen Wang
HZHailing Zhang
Hailing Zhang
TWTing Wang
Ting Wang

22 November 2019 in Cancer Biomarkers
Verified
Journal Article
Closed access
RGRuixiang Gao
Ruixiang Gao
ZWZhen Wang
Zhen Wang
QLQiang Liu
Qiang Liu
CYChunmei Yang
Chunmei Yang
Esophageal cancer is a common tumor with high mortality worldwide. In the present study, we aimed to investigate the prognostic significance and regulatory effects of miR-105 on cellular functions of esophageal cancer cells. The expression level of miR-105 was analyzed in esophageal cancer tissues and cell lines by qRT-PCR. Survival analysis was carried out using the Kaplan-Meier and the prognostic significance of miR-105 was analyzed with Cox regression analysis. The effects of miR-105 on cell proliferation, migration, and invasion abilities were detected with cellular experiments. We found that miR-105 was significantly upregulated in esophageal cancer tissues and cell lines, compared with the control group, respectively. Moreover, overexpression of miR-105 was significantly associated with positive lymph node metastasis, advanced TNM stage, and poor overall survival. In addition, overexpression of miR-105 promoted cell proliferation, migration, and invasion in esophageal cancer cells, while downregulation of miR-105 suppressed these cellular behaviors. Our findings indicate that a higher level of miR-105 predicts poorer prognosis in esophageal cancer patients, and miR-105 can promote esophageal cancer cell proliferation, migration, and invasion.

31 March 2023 in Acta Biomaterialia
Verified
Journal Article
Closed access
QWQi Wu
Qi Wu
BCBin Chen
Bin Chen
XYXin Yu
Xin Yu
ZWZhen Wang
Zhen Wang
ZSZhongyang Sun
Zhongyang Sun
JZJianning Zhao
Jianning Zhao

5 June 2026 in Cancer Immunology Research
Verified
Journal Article
Closed access
LYLingfeng Yu
Lingfeng Yu
MLMengpan Li
Mengpan Li
TLTongtong Liu
Tongtong Liu
JWJiangpeng Wu
Jiangpeng Wu
HMHuanliang Meng
Huanliang Meng
ZCZhengdong Cai
Zhengdong Cai
Osteosarcoma responds poorly to immune-checkpoint blockade (ICB), and the molecular drivers of its immune-cold state remain unclear. Using multi-omics analyses, we identified an immune-cold osteosarcoma subtype characterized by enrichment of protein SUMOylation and found the SUMO E1 subunit UBA2 as a key driver. UBA2 was anomalously upregulated in osteosarcoma cohorts and linked to worse outcomes. Functionally, UBA2 promoted autophagy, thereby exerting noncanonical protumor and immunosuppressive effects. Mechanistically, UBA2 catalyzed SUMO2-dependent SUMOylation of SESN2, enhancing autophagic flux. At the immune interface, UBA2 did not alter the expression of immune checkpoint molecules but reduced surface MHC-I through NBR1-mediated autophagy–lysosomal degradation, thereby limiting CD8+ T-cell infiltration. In vivo, pharmacologic UBA2 inhibition with ML-792 slowed tumor growth and sensitized tumors to ICB therapy. Together, these findings show that UBA2 links SUMOylation to autophagy-driven loss of antigen presentation and immune exclusion, highlighting the UBA2–autophagy–MHC-I axis as a therapeutic target and potential biomarker in osteosarcoma.

1 June 2021 in International Immunopharmacology
Verified
Journal Article
Closed access
KZKuang Kuang Zhu
Kuang Kuang Zhu
DSDong Sun
Dong Sun
XZXiaoqin Zou
Xiaoqin Zou
RLRuixia Liu
Ruixia Liu
ZWZhen Wang
Zhen Wang

2 July 2026
Verified
Other
Open access
LYLingfeng Yu
Lingfeng Yu
MLMengpan Li
Mengpan Li
TLTongtong Liu
Tongtong Liu
JWJiangpeng Wu
Jiangpeng Wu
HMHuanliang Meng
Huanliang Meng
ZCZhengdong Cai
Zhengdong Cai
Osteosarcoma responds poorly to immune-checkpoint blockade (ICB), and the molecular drivers of its immune-cold state remain unclear. Using multi-omics analyses, we identified an immune-cold osteosarcoma subtype characterized by enrichment of protein SUMOylation and found the SUMO E1 subunit UBA2 as a key driver. UBA2 was anomalously upregulated in osteosarcoma cohorts and linked to worse outcomes. Functionally, UBA2 promoted autophagy, thereby exerting noncanonical protumor and immunosuppressive effects. Mechanistically, UBA2 catalyzed SUMO2-dependent SUMOylation of SESN2, enhancing autophagic flux. At the immune interface, UBA2 did not alter the expression of immune checkpoint molecules but reduced surface MHC-I through NBR1-mediated autophagy–lysosomal degradation, thereby limiting CD8+ T-cell infiltration. In vivo, pharmacologic UBA2 inhibition with ML-792 slowed tumor growth and sensitized tumors to ICB therapy. Together, these findings show that UBA2 links SUMOylation to autophagy-driven loss of antigen presentation and immune exclusion, highlighting the UBA2–autophagy–MHC-I axis as a therapeutic target and potential biomarker in osteosarcoma.